Objective：To evaluate the effect of Xuezhikang Capsule（血脂康胶囊） on the serum levels of inflammatory factors such as tumor necrosis factor-α（TNF-α） and interleukin-6（IL-6） in patients with nonalcoholic fatt...Objective：To evaluate the effect of Xuezhikang Capsule（血脂康胶囊） on the serum levels of inflammatory factors such as tumor necrosis factor-α（TNF-α） and interleukin-6（IL-6） in patients with nonalcoholic fatty liver disease（NAFLD） and hyperlipidemia,and to explore whether it has anti-inflammatory effect.Methods：A total of 84 patients were randomly assigned to two groups with stratified block randomization, the treatment group（42 cases） and the control group（42 cases）.They were treated with Xuezhikang Capsule and polyene phosphatidylcholine capsule for twenty-four weeks,respectively.The changes in serum TNF-αand IL-6 were measured by enzyme linked immunosorbent assay before treatment and at the 12th and 24th week. Results：Compared with those before treatment,the serum levels of TNF-αand IL-6 significantly decreased in both groups after treatment（P〈0.01）.There was no significant change between the two groups for the treatments at different time points（P〉0.05） and between the two groups for treatments at the same time points （P〉0.05）.Conclusion：Xuezhikang Capsule can inhibit the serum inflammatory factor in patients with NAFLD and hyperlipidemia.展开更多
Objective：To observe the effect of combined therapy with Xuezhikang Capsule（血脂康胶囊,XZK） and Valsartan on left ventricular hypertrophy（LVH） and heart rate turbulence（HRT） in hypertensive patients. Methods：N...Objective：To observe the effect of combined therapy with Xuezhikang Capsule（血脂康胶囊,XZK） and Valsartan on left ventricular hypertrophy（LVH） and heart rate turbulence（HRT） in hypertensive patients. Methods：Ninety primary hypertensive patients with LVH were randomly assigned to three groups.Basic treatment,including aspirin,β-blockers,calcium antagonists,etc.were administered to all patients.Additionally, Valsartan（VS,80 mg once a day） was given to the 30 patients in the VS group.Valsartan（in the same dosage） and XZK（600 mg,twice a day） were given to the 32 patients in the Chinese medicine（CM） group,while none was given to the 28 patients in the control group.The therapeutic course lasted for 24 months.Changes in left ventricular mass index（LVMI） measured by cardiac ultrasonic indices,HRT parameters,including the original heart rate（TO） and slope coefficient（TS）,systolic and diastolic blood pressures（SBP and DBP）,as well as blood cholesterol level（TC） were measured before and after treatment.Results：After treatment,TO and LVMI were lowered,while TS increased in both the VS group and the CM group（P〈0.01）,but changed insignificantly in the control group.Significant differences between the CM group and the control group were shown in terms of TO,LVMI,SBP,DBP and TS（P〈0.01）;and between the CM group and the VS group in terms of TO,LVMI and TS（P〈0.01）.Moreover,HRT parameters showed an evident correlation with LVMI（r=0.519-0.635,P〈0.01）. Conclusion：Combined therapy with XZK and Valsartan can improve hypertensive LVH and HRT parameters, and lessen the damage on the autonomous nervous system.展开更多
目的运用网状Meta分析不同中成药联合西医常规治疗冠心病合并高脂血症的有效性和安全性。方法计算机检索中国知网、维普、万方、中国生物医学文献数据库、PubMed、Cochrane Library、Embase、Web of Science,搜集建库至2022年11月28日...目的运用网状Meta分析不同中成药联合西医常规治疗冠心病合并高脂血症的有效性和安全性。方法计算机检索中国知网、维普、万方、中国生物医学文献数据库、PubMed、Cochrane Library、Embase、Web of Science,搜集建库至2022年11月28日所发表的中成药治疗冠心病合并高脂血症的随机对照试验(randomized controlled trials,RCTs),采用RevMan 5.3、Stata 16.0软件进行数据统计分析。结果最终纳入77项RCTs,共8775例患者及8种中成药。网状Meta分析结果显示:在降低血清总胆固醇(total cholesterol,TC)方面,累积排序曲线下面积(surface under the cumulative ranking curve,SUCRA)排名前3的干预措施为通心络胶囊联合西医常规、脑心通胶囊联合西医常规、银丹心脑通软胶囊联合西医常规;在降低低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)方面,SUCRA排名前3的干预措施是通心络胶囊联合西医常规、脑心通胶囊联合西医常规、复方丹参滴丸联合西医常规;在提高临床总有效率方面,SUCRA排名前3的干预措施是脂必泰胶囊联合西医常规、麝香保心丸联合西医常规、血脂康胶囊联合西医常规;在改善心绞痛疗效方面,SUCRA排名前3的干预措施是银丹心脑通软胶囊联合西医常规、通心络胶囊联合西医常规、复方丹参滴丸联合西医常规;在改善心电图疗效方面,SUCRA排名前3的干预措施是复方丹参滴丸联合西医常规、银杏叶片联合西医常规、通心络胶囊联合西医常规;在增加心输出量(cardiac output,CO)方面,SUCRA排名前3的干预措施是通心络胶囊联合西医常规、银杏叶片联合西医常规、复方丹参滴丸联合西医常规;在安全性方面,试验组发生不良反应事件少于对照组。结论不同中成药联合常规西医治疗冠心病合并高脂血症有效且各有优势,但由于纳入的研究少,研究质量一般,不同治疗方案间疗效排序差异大,以上排序结果�展开更多
文摘Objective：To evaluate the effect of Xuezhikang Capsule（血脂康胶囊） on the serum levels of inflammatory factors such as tumor necrosis factor-α（TNF-α） and interleukin-6（IL-6） in patients with nonalcoholic fatty liver disease（NAFLD） and hyperlipidemia,and to explore whether it has anti-inflammatory effect.Methods：A total of 84 patients were randomly assigned to two groups with stratified block randomization, the treatment group（42 cases） and the control group（42 cases）.They were treated with Xuezhikang Capsule and polyene phosphatidylcholine capsule for twenty-four weeks,respectively.The changes in serum TNF-αand IL-6 were measured by enzyme linked immunosorbent assay before treatment and at the 12th and 24th week. Results：Compared with those before treatment,the serum levels of TNF-αand IL-6 significantly decreased in both groups after treatment（P〈0.01）.There was no significant change between the two groups for the treatments at different time points（P〉0.05） and between the two groups for treatments at the same time points （P〉0.05）.Conclusion：Xuezhikang Capsule can inhibit the serum inflammatory factor in patients with NAFLD and hyperlipidemia.
文摘Objective：To observe the effect of combined therapy with Xuezhikang Capsule（血脂康胶囊,XZK） and Valsartan on left ventricular hypertrophy（LVH） and heart rate turbulence（HRT） in hypertensive patients. Methods：Ninety primary hypertensive patients with LVH were randomly assigned to three groups.Basic treatment,including aspirin,β-blockers,calcium antagonists,etc.were administered to all patients.Additionally, Valsartan（VS,80 mg once a day） was given to the 30 patients in the VS group.Valsartan（in the same dosage） and XZK（600 mg,twice a day） were given to the 32 patients in the Chinese medicine（CM） group,while none was given to the 28 patients in the control group.The therapeutic course lasted for 24 months.Changes in left ventricular mass index（LVMI） measured by cardiac ultrasonic indices,HRT parameters,including the original heart rate（TO） and slope coefficient（TS）,systolic and diastolic blood pressures（SBP and DBP）,as well as blood cholesterol level（TC） were measured before and after treatment.Results：After treatment,TO and LVMI were lowered,while TS increased in both the VS group and the CM group（P〈0.01）,but changed insignificantly in the control group.Significant differences between the CM group and the control group were shown in terms of TO,LVMI,SBP,DBP and TS（P〈0.01）;and between the CM group and the VS group in terms of TO,LVMI and TS（P〈0.01）.Moreover,HRT parameters showed an evident correlation with LVMI（r=0.519-0.635,P〈0.01）. Conclusion：Combined therapy with XZK and Valsartan can improve hypertensive LVH and HRT parameters, and lessen the damage on the autonomous nervous system.
文摘目的运用网状Meta分析不同中成药联合西医常规治疗冠心病合并高脂血症的有效性和安全性。方法计算机检索中国知网、维普、万方、中国生物医学文献数据库、PubMed、Cochrane Library、Embase、Web of Science,搜集建库至2022年11月28日所发表的中成药治疗冠心病合并高脂血症的随机对照试验(randomized controlled trials,RCTs),采用RevMan 5.3、Stata 16.0软件进行数据统计分析。结果最终纳入77项RCTs,共8775例患者及8种中成药。网状Meta分析结果显示:在降低血清总胆固醇(total cholesterol,TC)方面,累积排序曲线下面积(surface under the cumulative ranking curve,SUCRA)排名前3的干预措施为通心络胶囊联合西医常规、脑心通胶囊联合西医常规、银丹心脑通软胶囊联合西医常规;在降低低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)方面,SUCRA排名前3的干预措施是通心络胶囊联合西医常规、脑心通胶囊联合西医常规、复方丹参滴丸联合西医常规;在提高临床总有效率方面,SUCRA排名前3的干预措施是脂必泰胶囊联合西医常规、麝香保心丸联合西医常规、血脂康胶囊联合西医常规;在改善心绞痛疗效方面,SUCRA排名前3的干预措施是银丹心脑通软胶囊联合西医常规、通心络胶囊联合西医常规、复方丹参滴丸联合西医常规;在改善心电图疗效方面,SUCRA排名前3的干预措施是复方丹参滴丸联合西医常规、银杏叶片联合西医常规、通心络胶囊联合西医常规;在增加心输出量(cardiac output,CO)方面,SUCRA排名前3的干预措施是通心络胶囊联合西医常规、银杏叶片联合西医常规、复方丹参滴丸联合西医常规;在安全性方面,试验组发生不良反应事件少于对照组。结论不同中成药联合常规西医治疗冠心病合并高脂血症有效且各有优势,但由于纳入的研究少,研究质量一般,不同治疗方案间疗效排序差异大,以上排序结果�
